09:54 AM EST - Cangene Corporation : announces that the United States Food and Drug Administration has approved Cangene's Botulism Antitoxin (Equine), Heptavalent (A, B, C, D, E, F, G) ("BAT") product for treatment of suspected or documented exposure to the botulinum neurotoxin A, B, C, D, E, F or G. Cangene's BAT received orphan drug designation and as a result of its approval, the product now has seven years of market exclusivity. BAT is the only botulism antitoxin available in the U.S. for treating naturally occurring, non-infant botulism, and for administering to patients under emergency conditions. Cangene Corporation
shares T.CNJ are trading up $0.17 at $2.92.
